n Southern African Journal of HIV Medicine - Updated guidelines for the use of rifamycins for the treatment of tuberculosis in HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors

Volume 2004, Issue 14
  • ISSN : 1608-9693
  • E-ISSN: 2078-6751



Extracted from text ... MARCH 2004 THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE 28 Two previously published reports provided guidelines for managing the pharmacological interactions that can result when patients are treated with protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for human immunodeficiency virus (HIV) infection together with rifamycins for tuberculosis (TB).1, 2 This article presents current data pertaining to interactions between these agents, with recommendations for their use from a group of Centers for Disease Control (CDC) scientists and outside expert consultants; these include initial recommendations for the PIs lopinavir/ritonavir, atazanavir, and fosamprenavir (a phosphate ester prodrug of amprenavir). The ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error